Of particular interest is the presence of SST5 in pituitary adenomas and NETs, for they already represent a valuable pharmacological target for SRIF analog treatment (van der Hoek et al., 2010; Veenstra et al., 2013). Here, SSTR5 is linked to pituitary gland adenoma.